查詢結果分析
來源資料
相關文獻
- Dyslipidemia in Uremic Patients Treated with HD and CAPD
- Dyslipidemia in Uremic Patients Treated with HD and CAPD
- Summary of National Guidelines for Diagnosis and Management of Lipid Disorders in Taiwan
- Summary of the National Guidelines for the Diagnosis and Management of Lipid Disorders in Taiwan
- 國人血脂異常診療及預防指引
- Blood Lipid Distrbution in Patients with Newly-Diagnosed, Non-Insulin-Dependent Diabetes Mellitus
- Effects of Fenofibrate and Gemfibrozil in Ethnic Chinese with Type IIb Dyslipidemia
- Atorvastatin (Lipitor[feb9])--可以對抗膽固醇與三酸甘油脂的新藥
- 高脂血症的運動處方
- Low Molecular Weight Heparin in Diabetic and Nondiabetic Hypercholesterolemic Patients Receiving Long-Term Hemodialysis
頁籤選單縮合
題 名 | Dyslipidemia in Uremic Patients Treated with HD and CAPD=慢性腎衰竭病患接受血液透析及連續可動性腹膜透析治療的血脂異常 |
---|---|
作 者 | 遲守華; 林裕峰; 盧國城; 戴良恭; 林石化; 謝善德; | 書刊名 | 醫學研究 |
卷 期 | 14:6 1994.05[民83.05] |
頁 次 | 頁379-388 |
分類號 | 415.816 |
關鍵詞 | 血液透析; 連續可動性腹膜透析; 血脂異常; 表面蛋白A-1; 表面蛋白B; 三酸甘油脂; 膽固醇; Hemodialysis; CAPD; Dyslipidemia; Apo A-1; Apo B; Triglyceride; Cholesterol; |
語 文 | 中文(Chinese) |
中文摘要 | 慢性腎衰竭病患接受血液透析或連續可動性腹膜透析治療,常有加重其血脂異常現象。為評估接受不同透析治療的尿毒症病患血脂異常情形,我們選擇了15位接受血液透析治療的病患、12位接受連續可動性腹膜透析治療病患、以及15位健康者,比較其血清三酸甘油脂、總膽固醇、表面蛋白A-I、和表面蛋白B等的濃度差異,並計算其表面蛋白A/I/B的比率。 結果顯示,接受血液透析病患比健康人有顯著的高血清三酸甘油脂(132.80±14.69 mg/dl vs 92.33±11.07 mg/dl, p<0.05)及低表面蛋白A-I(109.05±5.18 mg/dl vs 144.49±6.16 mg/dl, p<0.001)的濃度。相較於健康者,接受連續可動性腹膜透析治療者血清中也有有意義的高三酸甘油酯(262.08±64.21 mg/dl vs 92.33±11.07 mg/dl, p<0.01)、高總膽固醇(211.84±10.08 mg/dl vs 181.87±7.90 mg/dl, p<0.05)、低表面蛋白A-I (116.84±7.33 mg/dl vs 144.49±6.16 mg/dl, p<0.01)、及高表面蛋白B (128.73±5.55 mg/dl vs 107.71±5.55 mg/dl, p<0.05)濃度。至於兩種不同透析治療的比較,接受連續可動性腹膜透析者比接受血液透析者有較高的血清三酸甘油脂(p<0.05)、總膽固醇(p<0.05)、和表面蛋白B (p<0.05)濃度;同時前者亦有較低的表面蛋白A/I/B比率值。以上結果顯示,接受透析治療的病患可能有較高的血管粥樣硬化和心血管疾病罹患率,尤其是接受連續可動性腹膜透析治療者。 |
英文摘要 | Dyslipidemia is frequently encountered in patients undergoing either hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). To evaluate the dyslipidemia in uremic patients treated with HD and CAPD, serum lipid and apolipoprotein profiles including triglyceride (TG), total cholesterol (TC), apolipoprotein (Apo) A-I, Apo B were determined, and the anti-atherogenic risk ratio, Apo A-I/Apo B, among 15 HD patients, 12 CAPD patients, and 15 healthy controls were calculated. Comparing hemodialytic patients to normal healthy controls, there were also a significant decreased Apo A-I concentration (109.05±5.18 mg/dl vs. 144.49±6.16 mg/dl. p<0.001) and an increased TG concentration (132.80±14.69 mg/dl vs 92.33±11.07 mg/dl, p<0.05). There were a decreased Apo A-I concentration in CAPD patients (116.84±7.33 mg/dl vs 144.49±6.16 mg/dl, p<0.01): an increased Apo B concentration (128.73±5.55 mg/dl vs 107.71±5.55 mg/dl, p<0.05); an increased TC concentration (211.84±10.08 mg/dl vs 181.87±7.90 mg/dl, p<0.05); and an increased TG concentration (262.08±64.21 mg/dl vs 92.33±11.07 mg/dl, p<0.01) in the CAPD patients as compared to normal controls. Otherwise, there were significantly higher Apo B (p<0.05), TC (p<0.05), and TG (p<0.05) levels in the CAPD patients as compared to those of HD patients. The Apo A-I/Apo b ratio of HD patients were higher than in CAPD patients (p<0.05). It is concluded that CAPD patients revealed higher TG, TC and Apo B levels than those of normal controls and HD patients, and lower Apo A-I level than that of normal controls. There data might explain the higher incidence of complications of atherosclerotic and cardiovascular diseases in the dialytic patients, especially in the CAPD patients. |
本系統中英文摘要資訊取自各篇刊載內容。